Product News

Found 261,670 articles

• TISSIUM Raises €50M in Series D Funding to Finance its Commercial Launch and Platform Extension

  5/23/2023

  TISSIUM announced it has closed a Series D round of financing, raising €50 million from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation and Sofinnova Partners.

• OMRON Healthcare Celebrates 50 Years of Blood Pressure Monitor History

  5/23/2023

  OMRON Healthcare Co., Ltd. based in Muko City, Kyoto Prefecture, Japan, is proud to announce the celebration of its 50th anniversary in blood pressure monitor production this year.

• AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis

  5/23/2023

  AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis characterized by lung and skin fibrosis.

• Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology

  5/23/2023

  Valo Therapeutics Oy, the developer of novel, adaptable immunotherapies for cancer, announces that the first patient has been treated in its Phase I trial of PeptiCRAd-1 in three tumor types.

• Medigene AG Expands Patent Portfolio for its End-to-End Platform

  5/22/2023

  Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced that the Company has been issued a patent by the Japan Patent Office protecting its PD1-41BB switch receptor.

• US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

  5/22/2023

  Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo ® Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira® (adalimumab). Initially approved as a pre-filled syringe, Cyltezo is indicated to treat multiple chronic inflammatory diseases.

• Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023

  5/22/2023

  Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it has been added to the preliminary list of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 35th Russell indexes annual reconstitution.

• Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

  5/22/2023

  Enveric Biosciences, Inc. has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders.

• GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators

  5/22/2023

  GRI Bio, Inc. today provided a business outlook and highlighted upcoming milestones for its innovative pipeline of NKT cell modulators in development.

• Philips and Vanderbilt University Medical Center unite to define roadmap for decarbonizing radiology

  5/22/2023

  Royal Philips, a global leader in health technology, and Vanderbilt University Medical Center, home to the top-ranked adult and pediatric hospitals in the Southeastern U.S., announced a collaboration that aims to reduce the health system’s carbon footprint while determining a blueprint to guide industry efforts.

• ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia

  5/22/2023

  ABVC BioPharma, Inc. today announced that the Vitrargus® Phase II study at the Sydney Eye Hospital in New South Wales, Australia received ethical approval from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) on May 15, 2023.

• Coherus Announces U.S. Launch of UDENYCA® Autoinjector

  5/22/2023

  Coherus BioSciences, Inc. today announced that the single-dose (6mg/0.6mL), prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv) is now available for commercial sale in the United States.

• Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

  5/22/2023

  Creative Medical Technology Holdings, Inc. announced significant advances in the ongoing development of its ImmCelz® platform, the Company's cell-free system which has previously been validated to supercharge a patient's own cells to treat a number of immune disorders.

• Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder

  5/22/2023

  Clearmind Medicine Inc. today announced the selection of its first U.S. site for the company’s Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100 compound for the treatment of alcohol use disorder ("AUD").

• Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

  5/22/2023

  Rhythm Pharmaceuticals, Inc. announced a collaboration with Genpharm Services FZ LLC to commercialize IMCIVREE® in Gulf Cooperation Council countries, including Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman and Bahrain.

• Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

  5/22/2023

  Anixa Biosciences, Inc. today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the second patient in the ongoing clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

• Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

  5/22/2023

  Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo ® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

• Baylor Genetics Announces Neuromuscular Disorders Panel

  5/22/2023

  Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, announced the availability of a Neuromuscular Disorders Panel.

• Yaral Pharma Partners With EVERSANA to Support the Commercialization of Its Expanding Generics Portfolio

  5/22/2023

  Yaral Pharma Inc. today announced its expanding partnership with EVERSANA ® , a leading provider of commercialization services to the global life sciences industry, as its key commercialization partner to support the expansion of its portfolio of pain and endocrinology products in the U.S.

• Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer

  5/22/2023

  TellBio, Inc. announces publication of data that show the utility of CTCs isolated with TellDx to assess sensitivity and potential clinical benefit from an alternative tolerable therapeutic option in a cohort of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who progress on endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibition.